A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

• Status: RECRUITING
• Trial end date: 2027-02-01

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

• Phase: PHASE3

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Standard of Care